Fetal Development Risks from Lurbinectedin
Lurbinectedin (Zepzelca), an alkylating agent used for small cell lung cancer, causes embryo-fetal toxicity. It can lead to fetal harm, including death, when administered to pregnant women based on animal studies and its mechanism of binding DNA to inhibit cell proliferation, which affects rapidly dividing fetal cells.[1][2]
Animal data shows:
- In rats, intravenous doses about 0.25 times the human equivalent (mg/m²) caused embryo-fetal lethality, reduced fetal weight, and skeletal/renal abnormalities.
- In rabbits, doses around 0.1 times the human equivalent produced similar lethality and malformations.[1][3]
No human pregnancy data exists due to exclusion from clinical trials, but the risk is classified as high enough for mandatory warnings.[1]
FDA Pregnancy Category and Labeling
Lurbinectedin carries a boxed warning for embryo-fetal toxicity. It is Pregnancy Category Not Assigned (animal data only), with recommendations to verify pregnancy status before starting and advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose. Males should use contraception for 4 months post-dose.[1][2]
Recommendations for Patients Planning Pregnancy
Discontinue lurbinectedin if pregnancy occurs. A pregnancy exposure registry exists (contact 1-888-661-2832) to monitor outcomes. Breastfeeding is not advised during treatment and for 2 weeks after, as it may pass into milk.[1]
Mechanism Behind Fetal Harm
As a transcription inhibitor, lurbinectedin traps DNA-protein complexes, halting cell division. This genotoxic effect mirrors other chemotherapy agents, making it particularly dangerous during organogenesis (weeks 3-8 of pregnancy).[2][3]
[1]: FDA Label for Zepzelca (lurbinectedin)
[2]: Drugs.com - Lurbinectedin Pregnancy
[3]: RxList - Zepzelca Warnings